A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative
作者： Michael J. Pishvaian , R. Joseph Bender , Lynn M. Matrisian , Lola Rahib , Andrew Hendifar
DOI: 10.18632/ONCOTARGET.13225
关键词:
摘要: // Michael J. Pishvaian 1,2,* , R. Joseph Bender 1,* Lynn M. Matrisian 3 Lola Rahib Andrew Hendifar 4 William A. Hoos Sam Mikhail 5 Vincent Chung 6 Picozzi 7 Craig Heartwell 1 Kimberly Mason Katelyn Varieur Metasebia Aberra Subha Madhavan 1,2 Emanuel Petricoin III and Jonathan Brody 1,8 Perthera, Inc, McLean, VA, USA 2 Lombardi Comprehensive Cancer Center, Georgetown University Medical Washington, DC, The Pancreatic Action Network, Manhattan Beach, CA, Cedars-Sinai Los Angeles, Ohio State University, Columbus, OH, City of Hope Duarte, Virginia Seattle, WA, 8 Jefferson Pancreatic, Related Kimmel Thomas Philadelphia, PA, * These authors have contributed equally to this work Correspondence to: Brody, email: Keywords : cfDNA, pancreatic cancer, blood-based NGS Received June 15, 2016 Accepted September 25, Published November 08, Abstract Recent improvements in next-generation sequencing (NGS) technology enabled detection biomarkers cell-free DNA blood may ultimately replace invasive tissue biopsies. However, a better understanding the performance assays is needed prior routine clinical use. As part an IRB-approved molecular profiling registry trial ductal adenocarcinoma (PDA) patients, we facilitated testing 34 patients from multiple community-based high-volume academic oncology practices. 23 these also underwent traditional tumor tissue-based testing. cfDNA was not detected 9/34 (26%) patients. Overall concordance between low, with only 25% sensitivity for NGS. Mutations KRAS, major PDA oncogene, were 10/34 (29%) samples, compared 20/23 (87%) presence mutations circulating associated reduced overall survival (54% mutation-positive versus 90% mutation-negative). Our results suggest that setting previously treated, advanced PDA, liquid biopsies are yet adequate substitute Further refinement defining optimal patient population timing sampling improve value test.
jefferson.edu
elsevier.com
impactjournals.com参考文章(29)
Mark Sausen, Jillian Phallen, Vilmos Adleff, Siân Jones, Rebecca J Leary, Michael T Barrett, Valsamo Anagnostou, Sonya Parpart-Li, Derek Murphy, Qing Kay Li, Carolyn A Hruban, Rob Scharpf, James R White, Peter J O’Dwyer, Peter J Allen, James R Eshleman, Craig B Thompson, David S Klimstra, David C Linehan, Anirban Maitra, Ralph H Hruban, Luis A Diaz Jr, Daniel D Von Hoff, Julia S Johansen, Jeffrey A Drebin, Victor E Velculescu, None, Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients Nature Communications. ,vol. 6, pp. 7686- 7686 ,(2015) , 10.1038/NCOMMS8686
Patricia Valda Toro, Bracha Erlanger, Julia A. Beaver, Rory L. Cochran, Dustin A. VanDenBerg, Elizabeth Yakim, Karen Cravero, David Chu, Daniel J. Zabransky, Hong Yuen Wong, Sarah Croessmann, Heather Parsons, Paula J. Hurley, Josh Lauring, Ben Ho Park, Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA Clinical Biochemistry. ,vol. 48, pp. 993- 998 ,(2015) , 10.1016/J.CLINBIOCHEM.2015.07.097
Richard B. Lanman, Stefanie A. Mortimer, Oliver A. Zill, Dragan Sebisanovic, Rene Lopez, Sibel Blau, Eric A. Collisson, Stephen G. Divers, Dave S. B. Hoon, E. Scott Kopetz, Jeeyun Lee, Petros G. Nikolinakos, Arthur M. Baca, Bahram G. Kermani, Helmy Eltoukhy, AmirAli Talasaz, Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA PLOS ONE. ,vol. 10, pp. e0140712- ,(2015) , 10.1371/JOURNAL.PONE.0140712
Hideaki Kinugasa, Kazuhiro Nouso, Koji Miyahara, Yuki Morimoto, Chihiro Dohi, Koichiro Tsutsumi, Hironari Kato, Takehiro Matsubara, Hiroyuki Okada, Kazuhide Yamamoto, Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer. ,vol. 121, pp. 2271- 2280 ,(2015) , 10.1002/CNCR.29364
Lola Rahib, Benjamin D. Smith, Rhonda Aizenberg, Allison B. Rosenzweig, Julie M. Fleshman, Lynn M. Matrisian, Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States Cancer Research. ,vol. 74, pp. 2913- 2921 ,(2014) , 10.1158/0008-5472.CAN-14-0155
Nicola Waddell, Marina Pajic, Ann-Marie Patch, David K Chang, Karin S Kassahn, Peter Bailey, Amber L Johns, David Miller, Katia Nones, Kelly Quek, Michael CJ Quinn, Alan J Robertson, Muhammad ZH Fadlullah, Tim JC Bruxner, Angelika N Christ, Ivon Harliwong, Senel Idrisoglu, Suzanne Manning, Craig Nourse, Ehsan Nourbakhsh, Shivangi Wani, Peter J Wilson, Emma Markham, Nicole Cloonan, Matthew J Anderson, J Lynn Fink, Oliver Holmes, Stephen H Kazakoff, Conrad Leonard, Felicity Newell, Barsha Poudel, Sarah Song, Darrin Taylor, Nick Waddell, Scott Wood, Qinying Xu, Jianmin Wu, Mark Pinese, Mark J Cowley, Hong C Lee, Marc D Jones, Adnan M Nagrial, Jeremy Humphris, Lorraine A Chantrill, Venessa Chin, Angela M Steinmann, Amanda Mawson, Emily S Humphrey, Emily K Colvin, Angela Chou, Christopher J Scarlett, Andreia V Pinho, Marc Giry-Laterriere, Ilse Rooman, Jaswinder S Samra, James G Kench, Jessica A Pettitt, Neil D Merrett, Christopher Toon, Krishna Epari, Nam Q Nguyen, Andrew Barbour, Nikolajs Zeps, Nigel B Jamieson, Janet S Graham, Simone P Niclou, Rolf Bjerkvig, Robert Grützmann, Daniela Aust, Ralph H Hruban, Anirban Maitra, Christine A Iacobuzio-Donahue, Christopher L Wolfgang, Richard A Morgan, Rita T Lawlor, Vincenzo Corbo, Claudio Bassi, Massimo Falconi, Giuseppe Zamboni, Giampaolo Tortora, Margaret A Tempero, Royal North Shore Hospital Samra Jaswinder S. 39 Gill Anthony J. 39 Pavlakis Nick 39 Guminski Alex 39 Toon Christopher 39, Bankstown Hospital Asghari Ray 40 Merrett Neil D. 40 Pavey Darren 40 Das Amitabha 40, Liverpool Hospital Cosman Peter H. 41 Ismail Kasim 41 O’Connnor Chelsie 41, Westmead Hospital Lam Duncan McLeod Vincent W. 42 42 Pleass Henry C. 42 Richardson Arthur 42 James Virginia 42, Royal Prince Alfred Hospital Kench James G. 43 Cooper Caroline L. 43 Joseph David 43 Sandroussi Charbel 43 Crawford Michael 43 Gallagher James 43, Fremantle Hospital Texler Michael 44 Forest Cindy 44 Laycock Andrew 44 Epari Krishna P. 44 Ballal Mo 44 Fletcher David R. 44 Mukhedkar Sanjay 44, Sir Charles Gairdner Hospital Spry Nigel A. 45 DeBoer Bastiaan 45 Chai Ming 45, St John of God Healthcare Zeps Nikolajs 46 Beilin Maria 46 Feeney Kynan 46, Royal Adelaide Hospital Nguyen Nan Q. 47 Ruszkiewicz Andrew R. 47 Worthley Chris 47 Tan Chuan P. 47 Debrencini Tamara 47, Flinders Medical Centre Chen John 48 Brooke-Smith Mark E. 48 Papangelis Virginia 48, Greenslopes Private Hospital Tang Henry 49 Barbour Andrew P. 49, Envoi Pathology Clouston Andrew D. 50 Martin Patrick 50, Princess Alexandria Hospital O’Rourke Thomas J. 51 Chiang Amy 51 Fawcett Jonathan W. 51 Slater Kellee 51 Yeung Shinn 51 Hatzifotis Michael 51 Hodgkinson Peter 51, Austin Hospital Christophi Christopher 52 Nikfarjam Mehrdad 52 Mountain Angela 52, Victorian Cancer Biobank, Johns Hopkins Medical Institutes Eshleman James R. 54 Hruban Ralph H. 54 Maitra Anirban 54 Iacobuzio-Donahue Christine A. 54 Schulick Richard D. 54 Wolfgang Christopher L. 54 Morgan Richard A 54 Hodgin Mary 54, ARC-Net Centre for Applied Research on Cancer Scarpa Aldo 55 Lawlor Rita T. 55 Beghelli Stefania 55 Corbo Vincenzo 55 Scardoni Maria 55 Bassi Claudio 55, University of California, San Francisco Tempero Margaret A. 56, University of Glasgow Biankin Andrew V. 36 37 57 Grimmond Sean M. 37 38 Chang David K. 36 37 57 Musgrove Elizabeth A. 37 Jones Marc D. 36 37 Nourse Craig 37 38 Jamieson Nigel B. 37 57 Graham Janet S. 37 57, Greater Glasgow & Clyde National Health Service Biankin Andrew V. 36 37 57 Chang David K. 36 37 57 Jamieson Nigel B. 37 57 Graham Janet S. 37 57 Oien Karen 37 57 Hair Jane 57, None, Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. ,vol. 518, pp. 495- 501 ,(2015) , 10.1038/NATURE14169
Raphael Brandão Moreira, Renata D''Alpino Peixoto, Marcelo Rocha de Sousa Cruz, None, Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification. Case Reports in Oncology. ,vol. 8, pp. 83- 87 ,(2015) , 10.1159/000375483
Heinz-Josef Klümpen, Karla C.S. Queiroz, C. Arnold Spek, Carel J.M. van Noesel, Helmy C. Brink, Wendy W.J. de Leng, Roeland F. de Wilde, Elisabeth M.H. Mathus-Vliegen, G. Johan A. Offerhaus, Maarten A. Alleman, Anneke M. Westermann, Dirk J. Richel, mTOR Inhibitor Treatment of Pancreatic Cancer in a Patient With Peutz-Jeghers Syndrome Journal of Clinical Oncology. ,vol. 29, pp. e150- e153 ,(2011) , 10.1200/JCO.2010.32.7825
Agnieszka K. Witkiewicz, Elizabeth A. McMillan, Uthra Balaji, GuemHee Baek, Wan-Chi Lin, John Mansour, Mehri Mollaee, Kay-Uwe Wagner, Prasad Koduru, Adam Yopp, Michael A. Choti, Charles J. Yeo, Peter McCue, Michael A. White, Erik S. Knudsen, Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets Nature Communications. ,vol. 6, pp. 6744- 6744 ,(2015) , 10.1038/NCOMMS7744
Joseph M. Gozgit, Matthew J. Wong, Lauren Moran, Scott Wardwell, Qurish K. Mohemmad, Narayana I. Narasimhan, William C. Shakespeare, Frank Wang, Tim Clackson, Victor M. Rivera, Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models Molecular Cancer Therapeutics. ,vol. 11, pp. 690- 699 ,(2012) , 10.1158/1535-7163.MCT-11-0450